Advanced & Next-Gen Proteomics Ad Board

DeciBio conducted 11 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools (e.g. high plex, high sensitivity, hypothesis-free) have been adopted into research efforts today and how stakeholders expect their use of these tools to change over the next year. Many of these tools enable applications that far surpass the capabilities of ELISA and blotting methods, and stakeholders were asked to comment on the key use cases pursued with these newer technologies, rank top assay selection criteria, and provide feedback on assay providers / test vendors. The technologies discussed span many technical classes, (antibody, aptamer, protein sequencing) collectively called 'Next Generation Proteomics' (NGP), and this report provides a qualitative summary of these interviews. In response to each key interview question, DeciBio provides several condensed takeaways and a curated list of quotes indicative of stakeholder feedback.

‍

This report is organized around the responses to 9 key study questions

• What is your definition of Next Generation Proteomics (NGP)?
• What role does NGP play in drug discovery and development?
• How has the field of NGP advanced in the past year?
• What share of your proteomic testing was comprised of NGP in 2024 and what share of your proteomic testing do you expect to be NGP in 2025?
• What are the top three applications you  apply Next Generation Proteomics towards?
• What test features / characteristics are most important when selecting an NGP assay?
• What are the top pain points  associated with NGP assays today and what has been your experience adopting this tech?
• What is the bioinformatics pipeline you currently use to support the analysis of NGP data and what are your expectations from NGP vendors?
• What is the utility of multi-protein biomarkers?
• What percent of your spend on NGP in 2024 and 2025 can be attributed to the following NGP technology types (e.g., affinity-based platforms, protein sequencing, single cell proteomics)
• What is the current and expected future utility of affinity-based platforms?
• What is the current and expected future utility of single-cell proteomic platforms?
• What is the current and expected future utility of next generation protein sequencing?
• What is your familiarity with each of the following vendors (as compared to the Q1 2023 edition of this report)?
• What are the strengths and  weaknesses of each of the following NGP vendors you have used?
  • Alamar Biosciences, Bruker, Erisyon, MSD, Nautilus, Olink, QuantumSi, Quanterix, Seer, SomaLogic, Standard Biotools

‍

Companies Discussed

• Alamar Biosciences
• Bruker
• Erisyon
• MSD
• Nautilus
• Olink
• QuantumSi
• Quanterix
• Seer
• Somalogic
• Standard Biotools

‍

‍